Force recommendation. Comparing the before and after groups, the proportion of Hispanic women in the after group was lower and the method of payment differed between the groups (P <.0001). The prevalence of type 1 diabetes was increased in the after period, but overall rates of pregestational diabetes were similar (6.3% before vs 5.3% after [P > .05]). Risk factors for recurrent preeclampsia included maternal age >35 years (relative risk, 1.83; 95% confidence interval, 1.34e2.48), Medicaid insurance (relative risk, 2.08; 95% confidence interval, 1.15e3.78), type 2 diabetes (relative risk, 2.13; 95% confidence interval, 1.37e3.33), and chronic hypertension (relative risk, 1.96; 95% confidence interval, 1.44e2.66). The risk of recurrent preeclampsia was decreased by 30% in the after group (adjusted relative risk, 0.70; 95% confidence interval, 0.52e0.95). CONCLUSION: Rates of recurrent preeclampsia among women with a history of preeclampsia decreased by 30% after release of the US Preventive Services Task Force recommendation for aspirin for preeclampsia prevention. Future prospective studies should include direct measures of aspirin compliance, gestational age at initiation, and explore the influence of race and ethnicity on the efficacy of this primary prevention.
Key words: aspirin, preeclampsia, prevention P reeclampsia is a common obstetrical complication that affects 5e10% of pregnancies and is a major cause of multiorgan dysfunction and maternal morbidity resulting from generalized endothelial dysfunction. 1 Preeclampsia often results in fetal growth restriction and medically indicated preterm delivery with associated neonatal morbidity of prematurity (eg, respiratory issues, neonatal intensive care unit admission).
Estimates of recurrent preeclampsia risk vary, with most reports citing a risk of 15e25%, [2] [3] [4] although 65% of women with preeclampsia onset in the second trimester experienced recurrent preeclampsia in one study. 5 The variation in reported recurrence risk is likely explained by differences in patient populations including differences in known risk factors for recurrent preeclampsia (severity of preeclampsia, gestational age at onset). 6 In one prospective study from Sweden in 2009, among gravidae affected by preeclampsia in their first pregnancy, the risk of recurrent preeclampsia was 14.7% in the second pregnancy and 31.9% in the third pregnancy. 2 In this study, the authors advocated for 2 distinct preeclamptic cohorts, one of which experience severe, recurrent, and generally earlier onset and are affected by chronic maternal, genetic, and environmental factors.
The underlying etiology and pathophysiology of both primary and recurrent preeclampsia is incompletely understood but is thought to involve dysfunctional cytotrophoblastic invasion, placental ischemia, and release of inflammatory and endothelial mediators. 7, 8 At a mechanistic level, via inhibition of the cyclooxygenase enzymes, aspirin decreases the ratio of thromboxane to prostacyclins resulting in net increased uteroplacental blood flow.
9,10
Thus, aspirin retains the biological plausibility to reduce the occurrence of preeclampsia by relatively well-defined pharmacological mechanisms.
In September 2014, the US Preventive Services Task Force (USPSTF) published their recommendations regarding the use of low-dose aspirin for preeclampsia prevention for pregnant women at increased risk for preeclampsia, including women with a prior history of both early-and late-gestation preeclampsia. 11 Their recommendations were based on a systematic review and meta-analysis suggesting that aspirin was associated with absolute risk reductions 12 Since the publication of these recommendations, multiple meta-analyses have suggested an observable and significant impact of initiation of first or early midtrimester initiation of low-dose aspirin therapy for the prevention of both primary and recurrent preeclampsia among at-risk gravidae. 13, 14 However, evidence of a population-based impact of the USPSTF recommendation has not yet been undertaken.
The objective of this study was to evaluate the clinical impact of the USPSTF recommendation for low-dose aspirin for preeclampsia prevention on rates of recurrent preeclampsia.
Materials and Methods
Study design, subjects, and database characteristics This research study was approved by the Baylor College of Medicine Institutional Review Board (H-26364; H-33382; most recent approval May 16, 2016 ). This was a retrospective nested cohort study designed to evaluate the rates of preeclampsia among women with a history of preeclampsia before and after the late 2014 USPSTF recommendation aspirin for preeclampsia prevention recommendations.
Women with a history of preeclampsia were the cohort of interest because of the highest risk for recurrence and ability to standardize over time. In addition, it is possible that baseline comorbid occurrences rendering risk for primary preeclampsia (ie, chronic hypertension, type 1 and type 2 diabetes, morbid obesity) increased in the reference population. For these reasons, we chose to specifically examine the occurrence of recurrent preeclampsia rather than the occurrence of the disease overall.
We utilized a 2-hospital, single academic institution database of deliveries from August 2011 through June 2016. Based in Houston, TX, PeriBank is a comprehensive, institutional database and biobank focusing on detailed clinical data and accompanying specimens collected at delivery and curated at Baylor College of Medicine. A detailed description of PeriBank has been published previously. 15 At the time of admission, gravidae were enrolled by trained PeriBank research personnel after written informed consent was obtained. Up to 4900 variables of clinical data were sought from the electronic medical record, prenatal records and by in-person interview. The quality of the data was ascertained by regular verification of a subset of the inserted clinical data and by at least one board-certified maternalfetal medicine physician scientist (K.M.A.) as previously published. 15 Clinical data that were extracted for this study comprise the patient history (including prior and familial occurrence of preeclampsia, smoking status, nicotine and substance use, familial obstetrical history, and prenatal care clinics and providers), socioeconomic status (education, income, immigration status), and residential and workplace data (each trimester of pregnancy residence and work place 5 digit ZIP code). Not all 4900 potential PeriBank variables were used in this analysis.
Inclusion criteria
Subjects included in the current study were enrolled in our PeriBank database between August 2011 and June 2016 (n ¼ 17,256 deliveries). The index pregnancy is the most recent pregnancy in the database for each subject. All women with a history of preeclampsia in a prior pregnancy were identified. Women with multiple gestations were excluded, and only the first pregnancy during the time period for each woman was included. Women were assigned to the before and after groups based on the date of delivery for the index (most recent) pregnancy.
Outcome measures and data analysis
The primary outcome in this analysis was the incidence of recurrent preeclampsia in the index pregnancy. All clinical and demographic data for pregnancies enrolled into our study were obtained from PeriBank. Preeclampsia was defined by American College of Obstetrics and Gynecology diagnostic criteria. Of note, the diagnostic criteria for preeclampsia changed in 2013 before the guideline was implemented. 16, 17 A history of preeclampsia is documented in our database as is the gestational age at prior delivery; however, the severity of preeclampsia is not specified. The use of magnesium sulfate and preterm delivery were utilized as surrogates for preeclampsia with severe features.
Preterm delivery was defined as delivery prior to 37 weeks of gestation. Groups of interest were compared by a c 2 or Fisher exact test for categorical variables, a Student t test for normally distributed continuous variables, and a Wilcoxon rank-sum test for nonnormal continuous variables. Linear regression was performed for the trend in recurrent preeclampsia in the before and after groups.
In an effort to control for potential confounders, multivariate modeling was undertaken. Generalized linear models (GLMM, Proc GENMOD in SAS version 9.4; SAS Institute, Cary, NC) were used for estimation of RR, adjusted RR, and corresponding 95% CIs for binomial outcome variables (preeclampsia in this pregnancy [primary outcome], preterm birth, and magnesium sulfate for use in labor [secondary outcomes]).
Generalized linear mixed models (Proc GLIMMIX in SAS version 9.4) was used for the estimation of least square means for nonnormally distributed continuous outcome variables and comparison between study groups. Possible confounders were assessed initially and controlled for by including them in the regression models. Adjustments were made for maternal age, Hispanic ethnicity, method of payment, gestational age at the first visit, type 2 diabetes, chronic hypertension, and gestational age at diagnosis of preeclampsia in last pregnancy. A value of P < .05 was considered statistically significant. The number needed to treat (NNT) was calculated as the inverse of absolute risk reduction (absolute risk reduction ¼ control event rate (before) less the experimental event rate (after).
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Results
During the study period, 17,256 deliveries were captured in our PeriBank database. A total of 417 pregnancies were identified as high risk for preeclampsia based on a history of preeclampsia; 284 pregnancies before and 133 pregnancies after the USPSTF recommendation for low-dose aspirin for preeclampsia prevention (Table 1) . Comparing the before and after groups, the proportion of Hispanic gravidae in the after group was lower and the method of payment differed between the groups (P < .0001). The prevalence of type 1 diabetes was increased in the after period, but overall rates of pregestational diabetes were similar (6.3% before vs 5.3% after, P > .05).
There were no significant differences in maternal age (P ¼ .585), African American race (P ¼.252), gestational age at first visit (P ¼ .055), body mass index (BMI; P ¼ .969), smoking status (P ¼ .445), chronic hypertension (P ¼ .178), gestational age of diagnosis for prior preeclampsia (P ¼ .209), gestational age at delivery this pregnancy (P ¼.917), or preterm delivery this pregnancy (P ¼ .826).
Maternal age >35 years (RR, Figure 2, A and B) . There was a downward trend in the incidence of recurrent preeclampsia prior to the intervention, but the slope was not significant in the before or after period (P ¼ .086 and P ¼ .965, respectively). When the data were limited to 2 years before and 2 years after the recommendation, there was not a decreasing tend in preeclampsia rates, and the difference between before and after groups remained significant (P ¼ .02, Figure 2, C and D) .
There was no significant difference in the use of magnesium sulfate for seizure prophylaxis during labor (25.0% before vs 18.3% after; aRR, 0.71; 95% CI, 0.46e1.10) or preterm delivery (24.3% before vs 23.3% after; aRR, 0.99; 95% CI, 0.68e1.43). The NNT to prevent 1 case of preeclampsia for all women with a history of preeclampsia in our cohort was 6.
Comment
Rates of recurrent preeclampsia among women with a history of preeclampsia decreased by 30% after the USPSTF recommendation for low-dose aspirin for preeclampsia prevention. The decreased incidence of recurrent preeclampsia was not accounted for by differences in known accompanying risk factors for preeclampsia in our multivariable analysis. The quarterly representation of data in Figure 2B similarly shows no evidence of seasonal variation in the incidence of recurrent preeclampsia, suggesting that temporal seasonal variation alone could not account for our findings. 18, 19 Paradoxically, we did observe a higher proportion of at-risk women who did not experience recurrent preeclampsia, which argues against change in regional referral patterns or birthrates affecting our results.
Several randomized controlled trials and meta-analyses have been conducted to test the hypothesis that aspirin can reduce the incidence of preeclampsia. [20] [21] [22] [23] Two large trials from the Maternal-Fetal Medicine Unit Network and the Collaborative LowDose Aspirin Study in Pregnancy (CLASP) provided most of the data for subsequent meta-analyses. 24, 25 The Maternal-Fetal Medicine Unit conducted a multicenter, randomized, placebo-controlled trial of lowdose aspirin for the prevention of 
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ajog.org preeclampsia in 2503 women. 24 The study population was women deemed to be at high risk of preeclampsia based on pregestational diabetes requiring insulin, chronic hypertension, multifetal gestations, or a history of preeclampsia in prior pregnancies. The investigators found that aspirin did not lower the incidence of preeclampsia in any of these groups (RR, 0.90; 95% CI, 0.77e1.06).
The Collaborative Low-dose Aspirin Study in Pregnancy was a multinational trial including 9364 women who were enrolled to prevent or treat preeclampsia and fetal growth restriction. 25 The investigators found a 12% nonsignificant decrease in proteinuric preeclampsia in the aspirin group (RR, 0.88; 95% CI, 0.75e1.03).
A subsequent meta-analysis published in 2003 that included 14 trials of more than 12,000 women showed that aspirin reduced the incidence of preeclampsia and perinatal death (odds ratio, 0.86; 95% CI, 0.76e0.96, and odds ratio, 0.79; 95% CI, 0.64e0.96, respectively). 26 In 2007, the PARIS Collaborative Group published a meta-analysis with individual patient level data from 31 trials including 32,217 women. Women who received aspirin had 10% reduction in the relative risk of preeclampsia (RR, 0.90; 95% CI, 0.84e0.97), delivery before 34 weeks (RR, 0.90; 95% CI, 0.83e0.98), and pregnancy with a serious adverse outcome (RR, 0.90; 95% CI, 0.85e0.96). 27 More recent studies have examined the effect of prophylactic anticoagulation in addition to aspirin on placentamediated complications with conflicting results. [28] [29] [30] The evidence regarding the dose-dependent efficacy and impact of gestational age at initiation are similarly poorly defined. 31, 32 One novel finding of our study was related to estimates of at-risk recurrence when our cohort was stratified by its inherent racial and ethnic variation. Interestingly, the relative proportion of Hispanic women experiencing recurrent Risk factors for recurrent preeclampsia among the cohort overall Forest plot of risk factors for recurrent preeclampsia among the cohort overall, with relative risk and 95% confidence intervals.
BMI, body mass index; CI, confidence interval. ajog.org SMFM Papers preeclampsia in the post-USPSTF recommendation strata was lower, while the proportion of African American gravidae and those with chronic hypertension was higher. Because our cohort is largely Hispanic, we cannot distinguish whether these observations are due to relative over-or underpowering. However, the data trend is of potential interest, and although difficult to ascertain from this study alone, these findings potentially suggest that there may be racial and ethnic variation in responsiveness to low-dose aspirin prophylaxis for recurrence of preeclampsia.
The results of our study differ substantially from previous trials in that our effect size was much larger (overall effect sizes from larger trials were small with an approximately 10% reduction). 24, 25 However, our results are in agreement with the meta-analysis that prompted the USPSTF recommendation (RR, 0.76; Pregnancies affected by recurrent preeclampsia Pregnancies affected by recurrent preeclampsia (and those not affected) over time and before and after the USPSTF recommendation for aspirin for preeclampsia prevention. At risk was defined by gravidae documented as having had preeclampsia in a prior pregnancy. A, Trends in rates of recurrent preeclampsia, 2011e2016. B, Bar graph of recurrent preeclampsia by quarter, 2011e2016. C, Trend in rates of recurrent preeclampsia, 2013e2016 (2 years before and after the USPSTF recommendation). D, Scatter plot of rate of recurrent preeclampsia, 2013e2016 (2 years before and after the USPSTF recommendation). 95% CI, 0.62e0.95). 12 We speculate that in our patient population, which is largely Hispanic, aspirin may be particularly effective. Future pharmacogenomics studies and analyses may benefit from study design aimed to directly assess whether aspirin has varying degrees of effectiveness for preventing preeclampsia among different races and ethnicities; this would be in alliance with current precision medicine initiatives.
Our study has both limitations and strengths. Limitations of our study include the retrospective nature and inability to control for all potential confounders. Another limitation includes the lack of data on which women received aspirin, individual subject compliance with aspirin, and gestational age at initiation of therapy.
As an observational study, we are unable to assert a causal association; our findings suggest a temporal association with the USPSTF aspirin guideline for the prevention of preeclampsia with robust adjustments for potential confounders, which did not explain our findings.
Additionally, by design, our cohort included only women with a history of preeclampsia and did not include women without a history of preeclampsia with other risk factors for preeclampsia including those for whom aspirin is recommended (eg, multifetal gestation, chronic hypertension, pregestational diabetes, renal disease, and autoimmune disease). 11 However, a history of preeclampsia is the predictor for preeclampsia with reported 7-fold relative risk, 33 and the overall primary rate of preeclampsia is virtually unchanged across populations and over generations. Thus, the strata within which we chose to examine recurrence is a strength of our approach and limits ascertainment bias inherent to large population-based studies. Similarly, the large number of deliveries and manually abstracted data, rather than utilization of diagnosis codes, strengthen the validity our results over other population-based analyses.
Finally, the greatest strength of our study was its ability to estimate the effect of release of a USPSTF recommendation for the use of low-dose aspirin at a population-wide level, inclusive of inherent imperfect use and application. We observed a 30% risk reduction across the population, which could not be explained by any factor other than the temporal introduction of such guidelines. The clinical use of aspirin for the prevention of preeclampsia is estimated to decrease the rate of recurrent preeclampsia in women at the highest risk of recurrence in our practice, and our NNT estimate across the entirety of the population over time was 6. Aspirin is a low-cost intervention with widespread availability and proven ability to reduce morbidity and health care costs. 34, 35 The future for the study of aspirin for preeclampsia prediction is bright including planned studies to incorporate early screening tests for preeclampsia to determine eligibility for aspirin use. 36, 37 Future studies should include women with indications for aspirin other than a history of preeclampsia and further explore the influence of race and ethnicity on the preventive efficacy of low-dose aspirin. n
